// App-Quantinova.ai

414 : Results From the Dose Escalation Phase of a Randomized Phase 12 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Researchers

Presenter

  • Hagop M. Kantarjian

Principal Investigators

  • David Rizzieri

  • Wendy Stock

  • Casey L. O'Connell

  • Elizabeth A Griffiths

  • Karen Yee

  • Raoul Tibes

  • Guillermo Garcia-Manero

  • Farhad Ravandi

  • Katherine Walsh

  • Eric Feldman

  • Ellen K Ritchie

  • Arati V Rao

  • Carlos Decastro

  • Aaron D. Schimmer

  • Ruben A Mesa

  • Ibrahim Syed

  • Gavin Choy

  • Aram Oganesian

  • Pietro Taverna

  • Mohammad Azab

  • Woonbok Chung

  • Jean-Pierre Issa

Medical Centers

  • Princess Margaret Hospital, Toronto, ON, Canada

  • The Ohio State Univerisity, Columbus, OH

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

Locations

  • United States

  • Canada

Companies

  • Astex Pharmaceutical

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Thrombocytopenia

  • Neutropenia

  • Sepsis

Biomarkers

  • Long interspersed nucleotide element-1

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

  • Decitabine

  • SGI-110

Outcome

  • N/A

Study Design

  • randomized

  • pharmacodynamics

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved